| Latest Abbott Laboratories News Headlines |
| Date | Time | Source | |
| 11/19/2009 | 2:00PM | PRNUS | The Deal Names Abbott Top Dealmaker for Second Consecutive Year
Awards Recognize Industry-Leading Companies That Demonstrate Effective Strategic Use of Mergers and Acquisitions
ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE:ABT) as one of its Most Admired Corporate Dealmakers for the second consecutive year. The Deal honored Abbott... More...>> |
| 11/17/2009 | 8:30AM | PRNUS | Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
ABBOTT PARK, Ill. and WALTHAM, Mass., Nov. 17 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed... More...>> |
| 11/16/2009 | 3:00PM | PRNUS | Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients
ORLANDO, Fla., Nov. 16 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully... More...>> |
| 11/15/2009 | 6:28PM | PRNUS | Abbott Statement on ARBITER 6 - HALTS Results and Abbott's Niaspan (niacin extended-release)
Study results released today by the American Heart Association and the New England Journal of Medicine
ORLANDO, Fla., Nov. 15 /PRNewswire-FirstCall/ -- Results from the investigator-initiated ARBITER 6 - HALTS study showed patients at high cardiovascular risk had significant regression of atherosclerosis after 8 and... More...>> |
| 11/12/2009 | 9:00AM | PRNUS | Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Anti-NGF Compound Adds to Company's Early-Stage Pain Care Pipeline
ABBOTT PARK, Ill., Nov. 12 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care... More...>> |
| 11/11/2009 | 2:41PM | PRNUS | Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps
HOUSTON, Nov. 11 /PRNewswire/ -- The Houston trial law firm Arnold & Itkin LLP has filed five lawsuits against the makers of pain pumps and related medications based on claims that many of the companies' defective devices are causing irreversible shoulder damage among patients.
Currently, the attorneys at Arnold... More...>> |
| 11/03/2009 | 10:00AM | PRNUS | President of Tanzania and the Abbott Fund Dedicate Modern Emergency Medical Department
Facility is First in Tanzania to Meet International Standards in Emergency Medicine; Effort is Latest Result of Longstanding Partnership to Strengthen Tanzania's Health Care System
DAR ES SALAAM, Tanzania, Nov. 3 /PRNewswire/ -- For the first time, emergency room services meeting international standards will be a part... More...>> |
| 11/02/2009 | 11:00AM | PRNUS | Abbott Saving 1 Billion Gallons of Water Annually
Company Utilizing New Manufacturing Practices and Technologies
ABBOTT PARK, Ill., Nov. 2 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) announced today that it is saving 1 billion gallons of water annually since launching a comprehensive, global effort in 2004 to preserve natural resources through reducing use of water... More...>> |
| 11/02/2009 | 8:00AM | PRNUS | Abbott Completes Acquisition of Evalve, Inc.
ABBOTT PARK, Ill., Nov. 2 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) announced today that it has completed its acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves.
The acquisition provides Abbott with a leading presence in the growing area of... More...>> |
| 10/29/2009 | 11:00AM | PRNUS | Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois
Abbott Recognized with the Illinois Continuous Improvement Award for Eighth Time
ABBOTT PARK, Ill., Oct. 29 /PRNewswire/ -- Abbott (NYSE:ABT) announced today that it has received the annual Illinois Continuous Improvement Award for environmental excellence. It is the eighth time Abbott has received the award for its... More...>> |
| 10/22/2009 | 5:07PM | PRNUS | Abbott Opens New R&D Center at University of Illinois Research Park
CHAMPAIGN, Ill., Oct. 22 /PRNewswire-FirstCall/ -- Abbott, a global health care company today celebrated the dedication of its new Abbott Nutrition facility at the Research Park on the University of Illinois campus.
Abbott will use the facility to research and develop nutritional products for infants through adults... More...>> |
| 10/20/2009 | 5:16PM | PRNUS | Abbott Completes Visiogen Acquisition
ABBOTT PARK, Ill., Oct. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) today announced that it has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract... More...>> |
| 10/20/2009 | 8:05AM | PRNUS | FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
ABBOTT PARK, Ill., Oct. 20 /PRNewswire-FirstCall/ -- An important assay used to aid in the diagnosis of rheumatoid arthritis (RA) will soon be available on Abbott's ARCHITECT immunoassay analyzers. The FDA has granted 510(k) clearance for an antibody cyclic-citrulinated peptide, or anti-CCP assay, to run on the world... More...>> |
| 10/19/2009 | 9:00AM | PRNUS | Photo: ZonePerfect Indulgence(TM) Nutrition Squares Give Chocolate Lovers a Sensible Sweet-Tooth Option
Abbott Introduces New Decadent Nutrition Squares with Soft, Whipped Center for Chocolaty Indulgence
COLUMBUS, Ohio, Oct. 19 /PRNewswire/ -- Abbott (NYSE:ABT) today announced the introduction of ZonePerfect Indulgence(TM) Nutrition Squares, a decadent new snack with a soft, whipped center that will have chocolate lovers... More...>> |
| 10/14/2009 | 7:47AM | PRNUS | Abbott Reports 16.5 Percent Earnings Growth in Third Quarter; Raises Earnings Guidance for 2009
- Adjusted EPS Growth of 16.5 Percent (GAAP EPS Growth of 37.7 Percent) - - Company Raises Earnings-Per-Share Outlook for 2009 - - Worldwide Operational Sales Increased 8.4 Percent - - Worldwide Medical Products Operational Sales Increased 16.2 Percent - - Worldwide Nutritional Operational Sales Increased 13.1 Percent... More...>> |
| 09/30/2009 | 10:00AM | PRNUS | Abbott Cuts Use of Oil and Coal by 35 Percent
Company Also Reduces Electricity Usage by 32 Percent in Bid to Conserve Energy
ABBOTT PARK, Ill., Sept. 30 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) announced today that it has significantly reduced its use of both fossil fuels and electricity as part of a multi-faceted, company-wide effort to safeguard the environment... More...>> |
| 09/24/2009 | 3:25PM | PRNUS | Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
SAN FRANCISCO, Sept. 24 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable... More...>> |
| 09/24/2009 | 9:00AM | PRNUS | Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 24 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) will announce its third-quarter 2009 financial results on Wednesday, Oct. 14, 2009, before the market opens.
The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be... More...>> |
| 09/23/2009 | 4:42PM | PRNUS | Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investi
Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte
SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE:ABT) market-leading XIENCE V Everolimus Eluting Coronary Stent System demonstrated... More...>> |
| 09/23/2009 | 2:10PM | PRNUS | Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 Percent Reduction in Stent Thrombosis (Blood Clots) Compared to TAXUS - Low Event Rates across Multiple Subgroups of Complex Patients
SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/... More...>> |